Skip to main content
Premium Trial:

Request an Annual Quote

PMC Taps Leavitt for Leadership Award, Gerstel Nabs CEO Spot at Compugen, Corn Joins Quinterix SAB, and Others

NEW YORK (GenomeWeb News) - The Personalized Medicine Coalition has awarded its Leadership in Personalized Medicine Award to Michael Leavitt, secretary of the Department of Health and Human Services.
 
Leavitt has served as HHS secretary since January 2005. Prior to that, he headed the Environmental Protection Agency and was elected three times as the Governor of Utah.
 
Leavitt “has provided extraordinary leadership in the recognition of the importance of personalized medicine in health care,” Harvard Medical School’s Raju Kucherlapati said in a statement issued by the PMC.
 
Edward Abrahams, executive director of the PMC, said that Leavitt’s leadership “raised the level of awareness about the promise of personalized medicine to heights it would not have reached otherwise.”
 

 
Compugen has appointed Martin Gerstel as president and CEO, effective Jan. 1, 2009.
 
Gerstel, who has been chairman of the company since 1997, will take the reins from Alex Kotzer, who will remain a director of the company.
 
Gerstel previously was co-chairman and CEO of Alza, a member of the Pharmaceutical Research and Manufacturers of America, and he is a director of Evogene, Itamar Medical, the Weizmann Institute of Science, the Hebrew University, and other companies and organizations.
 

 
Quinterix Corporation has appointed Robert Corn to its scientific advisory board. Corn is a professor in chemistry and biomedical engineering at the University of California, Irvine, where he focuses on developing new methods for detecting binding of biomolecules to surfaces and chemical modification strategies to control specific and non-specific absorption of polymers to a variety of surfaces.
 

 
Lana Skirboll, director of the National Institutes of Health’s Office of Science Policy, has been named acting director of a reorganized Division of Program Coordination, Planning, and Strategic Initiatives.
 
Amy Patterson will serve as acting director of the science policy office.
 
Alan Krensky will leave his spot as head of the former Office of Portfolio Analysis and Strategic Initiatives, which is being subsumed by DPCPSI, and will go back to work at the National Cancer Institute, while serving as a senior advisor to the deputy director of NIH.  
 

 
Joel Saltz has joined Emory University’s Woodruff Health Sciences Center as the Georgia Research Alliance Eminent Scholar in Biomedical Informatics.
 
Saltz is director of Emory’s Center for Comprehensive Informatics and also serves as Emory Healthcare’s chief medical information officer.
 
Saltz formerly was chair of the Department of Biomedical Informaticsand a senior fellow at the Ohio Supercomputer Center at Ohio State University. Healso has worked with the National Cancer Institute’s Cancer Biomedical Informatics Grid.
 

 
Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in PEOPLE, a weekly roundup of industry comings and goings.

The Scan

Sick Newborns Selected for WGS With Automated Pipeline

Researchers successfully prioritized infants with potential Mendelian conditions for whole-genome sequencing or rapid whole-genome sequencing, as they report in Genome Medicine.

Acne-Linked Loci Found Through GWAS Meta-Analysis

Researchers in the European Journal of Human Genetics find new and known acne vulgaris risk loci with a genome-wide association study and meta-analysis, highlighting hair follicle- and metabolic disease-related genes.

Retina Cell Loss Reversed by Prime Editing in Mouse Model of Retinitis Pigmentosa

A team from China turns to prime editing to correct a retinitis pigmentosa-causing mutation in the PDE6b gene in a mouse model of the progressive photoreceptor loss condition in the Journal of Experimental Medicine.

CRISPR Screens Reveal Heart Attack-Linked Gene

Researchers in PLOS Genetics have used CRISPR screens to home in on variants associated with coronary artery disease that affect vascular endothelial function.